EACR-Boehringer Ingelheim Drugging and Regulating the MAP Kinase Pathway

We return to this topic for its second edition to focus on the basic and clinical aspects of the regulation of the Mitogen Activated Protein Kinase (MAPK) pathway, one of the most commonly mutated signalling pathways in human cancers. The programme will include new insights about the mechanisms of action of the new generation of pan-RAS inhibitors and rational combination therapies. Whether you work in academia or industry, if you’re interested in the role of the MAPK pathway in the context of genetically targeted and immune-based anticancer therapies then this is not a meeting you should miss! It will also focus on the mechanistic aspects of gene regulation, target validation, and drug development, as well as emerging translational and clinical opportunities of small molecule inhibitors. Speakers: Alberto Bardelli (University of Torino, Italy), Marco Hofmann (Boehringer Ingelheim, Austria), Colin Lindsay (Manchester Cancer Research Centre, UK), Piro Lito (MMSKC, USA), Sandra Misale (Johns Hopkins University, USA), Miriam Molina Arcas (Francis Crick Institute, UK), Marina Pasca di Magliano (University of Michigan Medical School, USA), Mallika Singh (Revolution Medicines, USA) Keywords: cancer research, oncology, MAPK pathway, small molecule inhibitors, intrinsic resistance, adaptive resistance, effective cancer therapy agents, pan-RAS inhibitors, gene regulation, target validation, drug development, clinical and translational opportunities, rational combination therapies, cross-resistance to immune modulators Deadlines: Abstract submission deadline: 16 December 2024 Registration deadline: 24 January 2025